Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway

Fig. 8

Ivermectin directly binds to EGFR. a Co-immunoprecipitation assay in HCT-8 cells treated with 3 μM IVM for 4 h with or without 10 nM EGF pretreatment for 2 h. Cell lysates were immunoprecipitated with non-specific IgG or anti-AVMs antibody that can cross-react with ABM and IVM. HCT-8 cells treated with ABM serve as positive control for the IP with anti-AVMs antibody. ‘IgG’ indicates the vehicle-treated cell lysates immunoprecipitated with non-specific IgG. ‘Input’ indicates the whole cell lysates. b-d Binding response (nm) between EGFR extracellular domain and different concentrations of ivermectin (IVM) (b), epidermal growth factor (EGF) (c) or the mixture of different concentrations of IVM with 25 nM EGF (d) was measured by Octet RED96 system. Abbreviations: IVM, ivermectin; ABM, abamectin; AVMs, avermectins; EGF, epidermal growth factor; EGFR, epithelial growth factor receptor. Western blots are representative of two independent experiments

Back to article page